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ABSTRACT
Background: Diabetes mellitus is associated with increased 
mortality rates in the setting of acute myocardial infarction. The 
aim of this study was to evaluate whether there are peculiari-
ties in the atherothrombotic process that might be implicated 
in increased risk for this outcome in patients with diabetes. 
Methods: Pilot study in a cohort of patients with ST-elevation 
acute myocardial infarction undergoing primary percutaneous 
coronary intervention and aspiration thrombectomy. Clinical 
and laboratory variables were evaluated in all of the cases. 
Thrombi were analyzed for histopathological features as well as 
immunohistochemical expression of CD34, CD61 and factor VIII. 
Results: Our sample included the first ten diabetic patients with 
material available for analysis, who were matched according 
to age, gender and time elapsed since myocardial infarction 
with ten patients without diabetes. There was no significant 
association between the immunohistochemical expression of 
CD34, CD61 and factor VIII with other histopathological, 
clinical and laboratory variables, including the presence of 
diabetes mellitus. Conclusions: In this preliminary analysis, 
it was not possible to demonstrate any significant difference 
in the expression of endothelial cell activity, platelet function 
and activation of the coagulation cascade between thrombi 
of patients with and without diabetes undergoing primary 
coronary intervention. 
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RESUMO
Características Imuno-Histoquímicas de  
Trombos Coronarianos de Pacientes com  
Infarto do Miocárdio com Elevação de ST e 
Diabetes Mellitus: Estudo Piloto
Introdução: No contexto do infarto agudo do miocárdio, o 
diabetes mellitus está associado à maior mortalidade. O objetivo 
deste estudo foi avaliar se existem, entre os diabéticos, pecu-
liaridades no processo de aterotrombose que poderiam estar 
implicadas em maior risco para tal desfecho. Métodos: Estudo 
piloto, proveniente de coorte de pacientes com diagnóstico 
de infarto agudo do miocárdio com elevação do segmento ST 
submetidos à intervenção coronária percutânea primária e à 
tromboaspiração. Foram estudadas variáveis clínico-laboratoriais 
de cada caso. Os trombos foram analisados quanto às carac-
terísticas histopatológicas e às expressões imuno-histoquímicas 
de CD34, CD61 e fator VIII. Resultados: Foram incluídos os 
primeiros dez pacientes portadores de diabetes mellitus com 
material disponível para análise, pareados por idade, sexo 
e tempo de evolução do infarto com dez pacientes sem 
diabetes mellitus. Não houve associação significativa entre 
as expressões imuno-histoquímicas de CD34, CD61 e fator 
VIII com relação às variáveis histopatológicas, laboratoriais 
e clínicas estudadas, inclusive com relação à presença de 
diabetes mellitus. Conclusões: Em análise preliminar, não foi 
possível demonstrar diferença significativa quanto à expressão 
da atividade de células endoteliais, da função plaquetária e da 
ativação da cascata de coagulação entre trombos de pacientes 
com e sem o diagnóstico de diabetes mellitus submetidos à 
intervenção coronariana primária.
DESCRITORES: Infarto do miocárdio. Diabetes mellitus. Trom-
bose coronária. Imuno-histoquímica. Intervenção coronária 
percutânea.
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C oronary artery disease (CAD) is the leading cause of death worldwide, with most adverse events being associated with the occurrence of acute 
myocardial infarction (AMI).1 With the optimization of 
antithrombotic therapies and reperfusion, a decrease 
in mortality from acute myocardial infarction with ST-
segment elevation (STEMI) has been observed.2 However, 
efforts are required to improve the management of this 
condition, as high rates of mortality have still been re-
ported.3 In most cases, STEMI is caused by the rupture 
of vulnerable atherosclerotic plaques associated with 
inflammatory activity and a dysfunctional endothelium. 
The ruptured plaque is the trigger for platelet activation 
and aggregation, and thrombin formation, resulting in 
total occlusion of the coronary artery by the thrombus.4
Primary percutaneous coronary intervention (PPCI) 
is considered the preferred method of reperfusion in 
AMI.5 In recent years, the adjunct thrombo aspiration 
technique has been increasingly used, with improvement 
in angiographic results and clinical outcomes in some 
studies.6 Additionally, thrombus removal has allowed 
for a new line of research regarding the analysis of 
the morphology, histology, and factors associated with 
different types of thrombi.7-9 Variables, such as red color 
and thrombus chronology, have been associated with 
increased mortality,10,11 but the physiopathological role 
of the different elements that constitute the thrombus 
has been seldom studied. 
Immunohistochemical analysis of thrombus as-
pirates can be an important complementary tool in 
the search for these answers. The expression of the 
endothelial cell activity, of platelet function, of and 
coagulation cascade activation can be estimated by 
the immunohistochemical expression of the antigens 
CD34, CD61, and factor VIII, respectively.12-15 In the 
scenario of STEMI, few studies have evaluated the im-
munohistochemical profile of intracoronary thrombus 
in vivo and its correlation with clinical variables.13-16 In 
this context, the importance of diabetes mellitus (DM) 
is well-known, either by increasing the risk of CAD 
and thrombosis, or because it is associated with higher 
mortality in STEMI.17,18 However, there are doubts as 
to whether this risk is mediated by differences in the 
physiopathological processes of atherothrombosis or by 
the increase in comorbidities associated with DM. Thus, 
this study aimed to evaluate the immunohistochemical 
expression of the antigens CD34, CD61, and factor VIII 
in coronary thrombi in patients with DM and STEMI.
METHODS
Patients
This was a pilot study of sample of patients con-
secutively admitted to this hospital with a diagnosis 
of STEMI, between December 2010 and November 
2012. STEMI was defined as chest pain at rest last-
ing more than 30 minutes, associated to ST-segment 
elevation of at least 1 mm in two contiguous leads in 
the frontal plane, or at least 2 mm in the horizontal 
plane, or associated with new left bundle branch block. 
Patients with evolution > 12 hours, younger than 18 
years, or those who refused to participate in the study 
were excluded. 
All participants signed an informed consent. The 
study was approved by the Ethics Committee in Research 
of Instituto de Cardiologia, Fundação Universitária de 
Cardiologia, Porto Alegre (RS), Brazil.
Clinical characteristics and follow-up
All patients were prospectively evaluated regard-
ing their clinical and demographic characteristics by 
one of the researchers. The clinical, laboratory, and 
angiographic variables were recorded in a dedicated 
database. During hospitalization, the patients were fol-
lowed daily by one of the investigators for verification 
of in-hospital events. After hospital discharge, patients 
were contacted by telephone or assisted at the outpa-
tient clinic for outcome assessment.
Percutaneous coronary intervention procedures
At admission, all patients received 300 mg of ace-
tylsalicylic acid and 300 to 600 mg of clopidogrel. For 
the performance of the PPCI procedure, 60 to 100 U/
kg of unfractionated heparin were administered. PPCI 
procedures were performed as recommended in the 
literature.19,20 Decisions regarding technical aspects of 
the procedure, such as access route (radial or femoral), 
whether or not to perform thromboaspiration, type 
and number of stents, and use of glycoprotein IIb/IIIa 
inhibitors were left to the discretion of the surgeons. 
Regarding thromboaspiration, three different catheters 
were used: Export (Medtronic Vascular Inc, Santa Rosa, 
CA, United States), Diver (Invatec, Brescia, Italy), or 
Pronto (Vascular Solutions, Minneapolis, MN, United 
States). In all cases, the aspirations were performed 
prior to balloon inflation, passing more than once 
through the site of occlusion. The aspirated blood and 
intracoronary material were retained on a filter.
Thrombus analysis
Immediately after thrombus removal from the coronary 
artery, the sample was embedded in 10% formalin and 
fixed in paraffin for 24 hours. The specimens were cut 
with a microtome and stained with the hematoxylin-
eosin method for histopathological analyses, which 
were performed by a pathologist blinded to the clinical 
characteristics of patients. The following characteristics 
of the thrombi were studied: volume (cm3), color (white 
or red), microscopic pattern (recent, with lysis, or in 
formation) and the percentage of leukocytes, fibrin, 
and erythrocytes, as well as the immunohistochemical 
expression of CD34, CD61, and factor VIII. Recent 
thrombi were characterized by the presence of fibrin, 
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leukocytes, and erythrocytes. Thrombi with lysis were 
characterized by the occurrence ofleukocyteapoptosis. 
As for thrombi in formation, they were characterized 
by the formation of loose connective tissue.7
For the immunehistochemistry analysis, 3-µm tissue 
sections were obtained, which were placed on silanized 
slides. To perform the immunehistochemistry analysis, 
each slide was submitted to deparaffinization, using 
xylene and hydration with ethanol. Antigen retrieval 
was performed in a microwave oven with a 10 mM/pH 
6.0 citric acid solution, in two cycles of nine minutes 
each, at 750 W. The blocking of endogenous peroxidase 
was performed with the use of 3% hydrogen peroxide 
(10 volumes). The primary antibody was diluted in 1% 
albumin and 0.1% sodium azide in PBS (phosphate-
buffered saline), incubated in a moist chamber for 30 
minutes at 37°C, and then the material was kept un-
der refrigeration at 4°C for 18 hours. The biotinylated 
secondary antibody was incubated in a moist chamber 
at 37° C, for 30 minutes, as well as the streptavidin-
biotin-peroxidase complex (StreptABC).  The chromogenic 
substrate used was 60 mg diaminobenzidine in PBS, 
and Harris hematoxylin was used as counter-stain. The 
following antibodies were used (Dako Corporation or 
Novocastra): CD34, CD61, and von Willebrand factor 
(factor VIII). In all cases, an immunehistochemistry panel 
was created. The expression obtained by blood cells 
and/or components of the specimen was revealed by 
the presence of brown staining in different areas of the 
sample. A strong positive expression was con sidered when 
the immunohistochemistry reaction showed strong and 
diffuse brown staining in several cells of  the analyzed 
tissue. Moderate positive expression was defined when 
the immunohistochemistry reaction showed amoderately 
intense brown (light brown) staining in some cells of 
the analyzed tissue.
Statistical Analysis
Data were analyzed using SPSS for Windows, 
considering significant values when p  <  0.05. Quan-
titative variables were expressed as mean ± standard 
deviation or as median and interquartile range (25-
75%). Categorical variables were expressed as absolute 
and relative frequency, analyzed by the chi-squared or 
Fisher’s exact test. The cellular infiltrate was analyzed 
using a semiquantitative scale.
RESULTS
During the study period, 310 patients were suc-
cessfully submitted to thromboaspiration (Thrombolysis 
in Myocardial Infarction [TIMI] 3 flow and thrombus-
recovery). In this analysis, the first ten patients with 
DM with material available for analysis, which were 
matched for age, gender, and time of infarction with ten 
patients without diabetes, were included in the study. In 
both groups, 60% of the sample were males, aged 55 
± 6 years and 56.5 ± 5.8 years, respectively, and with 
median time of AMI evolution of 3.9 hours (2.0 to 9.0 
hours) and 3.7 hours (2.8 to 9.3 hours), respectively.
The histopathological profile is shown in Table 1, and 
the immunohistochemical profile in Table 2. Regarding 
CD34 expression, there was a trend of association with 
presence of fibrin in thrombus and higher serum levels 
of fibrinogen. There was no association with other clini-
c al, laboratory, or histological characteristics (Table 3). 
The association between the expression of CD61 
antibodies and factor VIII and the analyzed variables 
(Tables 4 and 5) showed no statistically significant 
differences, except for a trend of association between 
the expression of CD61 antibodies and the presence 
of erythrocytes in the thrombus.
DISCUSSION
In this pilot study, there was no significant associ-
ation between the immunohistochemical expression of 
CD34, CD61, and factor VIII proteins with the analyzed 
histopathological, laboratory and clinical variables, 
including the presence of DM. There was, however, 
TABLE 1 
Histopathological characteristics of  
thrombi in the study patients
Case
Type of 
thrombus
Leukocytes 
(%)
Fibrin 
(%)
Erythrocytes 
(%)
1 With lysis 
focus
10 40 50
2 With lysis 
focus
5 90 5
3 Formation 5 70 25
4 Formation 15 65 20
5 Recent 20 70 10
6 Recent 5 45 50
7 Recent 10 50 40
8 Formation 5 90 5
9 Recent 30 50 20
10 Recent 30 50 20
11 Formation 10 80 10
12 With lysis 
focus
10 60 30
13 Recent 5 35 60
14 Formation 10 50 40
15 Recent 10 45 45
16 Formation 5 50 15
17 Recent 35 50 15
18 Recent 5 60 35
19 With lysis 10 50 40
20 Recent 10 20 70
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TABLE 2  
Immunohistochemical panel
Case
Diabetes 
mellitus CD34 Factor VIII CD61
1 No Positive Positive, 
strong
Positive, 
strong
2 Yes Negative Positive, 
strong
Positive, 
strong
3 No Positive Positive, 
strong
Positive, 
strong
4 No Positive Positive, 
strong
Positive, 
strong
5 No Negative Positive, 
strong
Positive, 
strong
6 Yes Negative Positive, 
strong
Positive, 
strong
7 No Negative Positive, 
strong
Positive, 
strong
8 Yes Negative Positive, 
strong
Positive, 
strong
9 No Positive Positive, 
strong
Positive, 
strong
10 No Positive Positive, 
strong
Positive, 
strong
11 No Positive Positive, 
strong
Positive, 
strong
12 No Negative Positive, 
moderate
Positive, 
moderate
13 No Positive Positive, 
strong
Positive, 
strong
14 Yes Positive Positive, 
strong
Positive, 
strong
15 Yes Positive Positive, 
strong
Positive, 
strong
16 Yes Negative Positive, 
strong
Positive, 
strong
17 Yes Positive Positive, 
strong
Positive, 
strong
18 Yes Positive Positive, 
strong
Positive, 
strong
19 Yes Positive Positive, 
strong
Positive, 
strong
20 Yes Positive Positive, 
moderate
Positive, 
strong
TABLE 3  
Association between CD34 expression and  
clinical-laboratory and histological variables
Expressionof CD34/variable p-value
Type of thrombus 0.77
Color of thrombus 0.53
Volume of thrombus 0.33
Presence of leukocytes 0.19
Presence of fibrin 0.06
Presence of erythrocytes 0.08
Diabetes mellitus 0.64
Systemic arterial hypertension 0.53
Body mass index 0.69
Smoking 0.78
HDL cholesterol 0.96
Total cholesterol 0.12
High-sensitive CRP 0.66
Triglycerides 0.79
Fibrinogen 0.07
Clopidogrel 0.64
Glycoprotein IIb/IIIa inhibitor 0.16
HDL, high-density lipoprotein; CRP, C-reactive protein.
TABLE 4 
Association between the expression of CD61 and 
clinical-laboratory and histological variables
Expression of CD61/variable p-value
Type of thrombus 0.21
Color of thrombus 0.37
Volume of thrombus 0.69
Presence of leukocytes 0.57
Presence of fibrin 0.19
Presence of erythrocytes 0.06
Diabetes mellitus 0.86
Systemic arterial hypertension 0.21
Body mass index 0.16
Smoking 0.28
HDL cholesterol 0.28
Total cholesterol 0.27
High-sensitive CRP 0.35
Triglycerides 0.27
Fibrinogen 0.26
Clopidogrel 0.74
Glycoprotein IIb/IIIa inhibitor 0.58
HDL, high-density lipoprotein; CRP, C-reactive protein.
a trend of association of CD34 expression with fibrin 
content in the thrombus and higher levels of serum 
fibrinogen, as well as a trend of association between 
CD61 expression and the presence of erythrocytes.
Different authors have proposed immunohistochem-
istry techniques as an additional tool for histopatho-
logical analysis, in order to increase the sensitivity for 
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recognition of thrombus-forming components, either 
at vascular or cavity level, using surgically extracted 
specimens or those obtained from autopsies.12,21 Such 
studies, when performed in patients with acute coronary 
syndromesin vivo, are scarce in the literature.13,15,16,22
Ikuta et al.22 compared material extracted from 
individuals with stable angina vs. patients with unstable 
angina, and found higher platelet aggregation and acti-
vation in the second group, demonstrated respectively, 
by increased immunoreactivity of glycoprotein IIb/IIIa 
(p  <  0.0005) and P-selectin (p  <  0.0001). A higher 
concentration of neutrophils was also identified in the 
plaques of unstable patients. In another study, which 
evaluated thrombi in the context of STEMI treated by 
mechanical reperfusion, a negative correlation between 
platelet content and the time elapsed since the onset of 
pain was demonstrated. Furthermore, the rate of cells 
expressing CD34 showed a positive correlation with 
restenosis in the follow-up (correlation coefficient = 
0.76, p  =  0.01).13
In a recent study, which highlighted the potential 
practical applicability of a greater knowledge of throm-
bus structure, Sambola et al.15 assessed the thrombotic 
burden in aspirates from ten patients undergoing PPCI, 
compared to ten patients undergoing rescue PCI after 
ineffective response to tenecteplase. In the latter group 
of patients, higher levels of fibrin (p = 0.016), P-selectin 
(p = 0.03), and von Willebrand factor (p  = 0.03) were 
detected. 
Although evidence indicates increased platelet re-
activity and coagulability, as well asimpaired fibrinolysis 
in patients with type 2DM,23 the immunehistochemical 
profile of the present diabetic patients was not differ-
ent from that of non-diabetics, even after matching the 
groups for important confounding factors, such as age, 
gender, and time of STEMI evolution. These findings 
were also different from the results found by Yamashita 
et al.,16 who observed a significantly lower number of 
CD34 positive cells in thrombi of patients with type 2 
DM. It is believed that this cell grouping can inhibit 
the formation and facilitate thrombus organization, so 
that its shortage may negatively impact the prognosis. 
Furthermore, no associations with statistical significance 
were observed between the CD34, CD61, or factor VIII 
antigens and other clinical variables or components of 
the thrombus. 
The main limitation of this pilot study was its small 
sample, which may have contributed to the lack of dif-
ference between groups. Conversely, the publication of 
these results can alert researchers and interventionists 
to the importance of immunohistochemical analysis in 
coronary thrombi in patients with STEMI.
CONCLUSIONS
In this preliminary analysis, it was not possible to 
demonstrate any significant differences regarding the 
expression of endothelial cell activity, platelet function, 
and coagulation cascade activation between thrombi of 
diabetic and non-diabetic patients undergoing primary 
coronary intervention and treatment of acute myocardial 
infarction with ST-segment elevation.
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TABLE 5  
Association between factor VIII expression and 
clinical-laboratory and histological variables
Expressionof factor VIII/variable p-value
Type of thrombus 0.51
Color of thrombus 0.15
Volume of thrombus 0.49
Presence of leukocytes 0.28
Presence of fibrin 0.59
Presence of erythrocytes 0.19
Diabetes mellitus 0.58
Systemic arterial hypertension 0.37
Body mass index 0.14
Smoking 0.71
HDL cholesterol 0.44
Total cholesterol 0.26
High-sensitive CRP 0.37
Triglycerides 0.26
Fibrinogen 0.22
Clopidogrel 0.75
Glycoprotein IIb/IIIa inhibitor 0.36
HDL, high-density lipoprotein; CRP, C-reactive protein.
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